Fulton Breakefield Broenniman’s Alexion Pharmaceuticals ALXN Stock Holding History

Fulton Breakefield Broenniman’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-32,748	Closed	-$4.01M	–	118
2016 Q3	$4.01M	Sell	32,748 -1,752	-5%	-$226K	0.81%	55
2016 Q2	$4.03M	Buy	34,500 +484	+1%	+$68.7K	0.82%	53
2016 Q1	$4.74M	Sell	34,016 -1,279	-4%	-$188K	1.04%	43
2015 Q4	$6.73M	Buy	35,295 +1,005	+3%	+$176K	1.49%	24
2015 Q3	$5.36M	Buy	34,290 +8,783	+34%	+$1.6M	1.26%	33
2015 Q2	$4.61M	Buy	+25,507	New	+$4.4M	1.01%	46

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fulton Breakefield Broenniman's ALXN Position: Q4 2016 in Review

Fulton Breakefield Broenniman sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 32,748 shares — an estimated $4.01M sold.

Fulton Breakefield Broenniman first reported a position in ALXN in Q2 2015 and held it in 6 quarters. The position peaked at $6.73M in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Fulton Breakefield Broenniman reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Fulton Breakefield Broenniman sold 32,748 Alexion Pharmaceuticals shares in Q4 2016, an estimated $4.01M.
Fulton Breakefield Broenniman first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Fulton Breakefield Broenniman's Alexion Pharmaceuticals position peaked at $6.73M in Q4 2015.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Fulton Breakefield Broenniman's 13F filing for Q4 2016, filed 3 Feb 2017.